课题基金 / 基金详情

Genotyping and Phenotyping the Hepatitis C Drug Target NS5A

Genotyping and Phenotyping the Hepatitis C Drug Target NS5A
丙型肝炎药物靶点 NS5A 的基因分型和表型分析
批准号:
8195980
负责人:
ROBERT T STRIKER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2012-06-30
关键词:
Adverse effectsAffinityAntiviral AgentsAntiviral TherapyBiochemicalBreedingCaringCatalogingCatalogsCellsChronic Hepatitis CClinical DataClinical TrialsCommunicable DiseasesConsensus SequenceContractsCost of IllnessCyclophilinsCyclosporineDataDatabasesDevelopmentDiseaseDrug CombinationsDrug Delivery SystemsDrug toxicityEpidemicEvolutionFDA approvedFamilyGeneticGenetic DatabasesGenetic RecombinationGenetic VariationGenotypeHIVHealthHealthcare SystemsHepatitis CHepatitis C virusImmuneImmunoprecipitationImmunosuppressionImmunosuppressive AgentsIn VitroIndustryInterferonsInvestmentsLeadLightLinkLiverLiver diseasesMalignant neoplasm of liverMono-SMorbidity - disease rateNon-Hodgkin&aposs LymphomaNonstructural ProteinOrgan TransplantationOutcomePatient CarePatientsPeptidylprolyl IsomerasePharmaceutical PreparationsPharmacogenomicsPhasePhenotypePopulationPredispositionProteinsPublic HealthRecombinantsRelative (related person)RepliconResearchResearch DesignResearch MethodologyResistanceResistance developmentResourcesRibavirinRoleSamplingSerumSiteSolidStagingSystemTestingTherapeuticTimeTransfusionTransplant RecipientsTransplantationUnited StatesUnited States Department of Veterans AffairsVariantVeteransVietnamViralViral Nonstructural ProteinsViral ProteinsViral Regulatory ProteinsViremiaVirusanti-hepatitis Cbaseburden of illnesscombatcostcyclophilin Beffective therapyfitnessfunctional genomicshigh riskimprovedin vivoinhibitor/antagonistinsightliver transplantationmortalitymutantpathogenpre-clinicalpressurepreventprotein foldingpublic health relevanceresponserisk benefit ratiosmall moleculetreatment responsetreatment strategyviral resistancevirus genetics

项目成果

ROBERT T STRIKER的其他基金

相似基金

相关文献

期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel selective substituted aminofurazans kinase inhibitors for Drug resistant Bacteria
Novel selective substituted aminofurazans kinase inhibitors for Drug resistant Bacteria
Genotyping and Phenotyping the Hepatitis C Drug Target NS5A
Genotyping and Phenotyping the Hepatitis C Drug Target NS5A
海外基金